|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2007-10-16
|
|
pubmed:abstractText |
Neutral 5-substituted 4-anilinoquinazolines addressed high in vivo clearance and phospholipidosis associated with previous basic compounds. A representative compound 8a inhibited tumor growth in a mouse xenograft model when co-administered with the cytochrome P450 inhibitor 1-aminobenzotriazole (ABT), and data are consistent with pharmacology primarily reflecting inhibition of erbB2 receptor tyrosine kinase.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:BallardPeterP,
pubmed-author:BarlaamBernard CBC,
pubmed-author:BradburyRobert HRH,
pubmed-author:DishingtonAllanA,
pubmed-author:HennequinLaurent F ALF,
pubmed-author:HickinsonD MarkDM,
pubmed-author:HollingsworthIan MIM,
pubmed-author:KettleJason GJG,
pubmed-author:KlinowskaTeresaT,
pubmed-author:OgilvieDonald JDJ,
pubmed-author:PearsonStuart ESE,
pubmed-author:ScottJames SJS,
pubmed-author:SulemanAbidA,
pubmed-author:WhittakerRobinR,
pubmed-author:WilliamsEmma JEJ,
pubmed-author:WoodRobinR,
pubmed-author:WrightLindsayL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6326-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17869514-Administration, Oral,
pubmed-meshheading:17869514-Aniline Compounds,
pubmed-meshheading:17869514-Animals,
pubmed-meshheading:17869514-Antineoplastic Agents,
pubmed-meshheading:17869514-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17869514-Cell Proliferation,
pubmed-meshheading:17869514-Dogs,
pubmed-meshheading:17869514-Drug Synergism,
pubmed-meshheading:17869514-Mice,
pubmed-meshheading:17869514-Molecular Structure,
pubmed-meshheading:17869514-Neoplasms,
pubmed-meshheading:17869514-Quinazolines,
pubmed-meshheading:17869514-Rats,
pubmed-meshheading:17869514-Receptor, erbB-2,
pubmed-meshheading:17869514-Triazoles,
pubmed-meshheading:17869514-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
|
|
pubmed:affiliation |
Cancer and Infection Research, AstraZeneca, Mereside, Alderley Park, Macclesfield, UK.
|
|
pubmed:publicationType |
Journal Article
|
